title: [Adverse effects and hemodynamic effects of nifedipine as a tocolytic].
abstract: OBJECTIVE
  To describe maternal and fetal adverse effects, in particular cardiorespiratory, of nifedipine as tocolytic, as well as effects on hemodynamic parameters.
  
  
  METHODS
  A retrospective evaluative study describing the use of nifedipine as tocolytic at CHU Sainte-Justine in Montreal. Demographic data as well as maternal blood pressure and adverse effects, and maternal and fetal heart rate were collected from medical records of women treated with nifedipine following our tocolysis protocol between January 1st 2004 and March 1st 2007.
  
  
  RESULTS
  The medical records of 213 pregnant women were included in the study. Cardiorespiratory adverse effects were noted in 69 (32.4%); of these, 19 (8.9%) had serious cardiorespiratory adverse events, including 6 acute pulmonary edema or overload. Mean maternal systolic and diastolic blood pressures were significantly decreased and mean maternal and fetal heart rates were significantly increased after the bolus dose. Other adverse effects were reported for 100 (46.9%) women.
  
  
  CONCLUSIONS
  Nifedipine may cause cardiorespiratory adverse effects warranting a close monitoring.
authors.affiliation: Service de pharmacie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France; Faculté de pharmacie, université d'Angers, 16, boulevard Daviers, 49045 Angers, France. Electronic address: laspiesser-robelet@chu-angers.fr.
authors.forename: L
authors.initials: L
authors.lastname: Spiesser-Robelet
authors.affiliation: Département de pharmacie, CHU Sainte-Justine, faculté de pharmacie, université de Montréal, Montréal, Québec, Canada.
authors.forename: B
authors.initials: B
authors.lastname: Martin
authors.affiliation: Département de pédiatrie, CHU Sainte-Justine, faculté de médecine, université de Montréal, Montréal, Québec, Canada.
authors.forename: A-M
authors.initials: AM
authors.lastname: Carceller
authors.affiliation: Département de pharmacie, CHU Sainte-Justine, faculté de pharmacie, université de Montréal, Montréal, Québec, Canada.
authors.forename: J-F
authors.initials: JF
authors.lastname: Bussières
authors.affiliation: Département de pharmacie, CHU Sainte-Justine, faculté de pharmacie, université de Montréal, Montréal, Québec, Canada.
authors.forename: K
authors.initials: K
authors.lastname: Touzin
authors.affiliation: Département d'obstétrique et gynécologie, CHU Sainte-Justine, faculté de médecine, université de Montréal, Montréal, Québec, Canada.
authors.forename: F
authors.initials: F
authors.lastname: Audibert
authors.affiliation: Département de pédiatrie, CHU Sainte-Justine, faculté de médecine, université de Montréal, Montréal, Québec, Canada.
authors.forename: C
authors.initials: C
authors.lastname: Lachance
authors.affiliation: Département de pharmacie, CHU Sainte-Justine, faculté de pharmacie, université de Montréal, Montréal, Québec, Canada.
authors.forename: E
authors.initials: E
authors.lastname: Ferreira
mesh_terms: D001794:Blood Pressure / Q000187:drug effects*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006340:Heart Rate, Fetal / Q000187:drug effects; D006801:Humans; D009543:Nifedipine / Q000009:adverse effects*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced*; D011654:Pulmonary Edema / Q000139:chemically induced*; D011792:Quebec; D015149:Tocolytic Agents / Q000009:adverse effects*
chemical_list: D015149:Tocolytic Agents; D009543:Nifedipine
keywords: Adverse effects; Effets indésirables; Nifedipine; Nifédipine; Tocolyse; Tocolytic